Gudrun Schleiermacher

List of Publications by Year
in descending order

146 papers	10,615 citations	47006 47 h-index	36028 97 g-index
155 all docs	155 docs citations	155 times ranked	11892 citing authors

#	Article	IF	Citations
1	Neuroblastoma. Nature Reviews Disease Primers, 2016, 2, 16078.	30.5	907
2	Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics, 2012, 28, 423-425.	4.1	847
3	Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature, 2008, 455, 967-970.	27.8	787
4	Advances in Risk Classification and Treatment Strategies for Neuroblastoma. Journal of Clinical Oncology, 2015, 33, 3008-3017.	1.6	637
5	Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nature Genetics, 2015, 47, 864-871.	21.4	451
6	Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries. Nature Genetics, 2017, 49, 1408-1413.	21.4	331
7	International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. British Journal of Cancer, 2009, 100, 1471-1482.	6.4	330
8	Germline Mutations of the Pairedâ€“Like Homeobox 2B (PHOX2B) Gene in Neuroblastoma. American Journal of Human Genetics, 2004, 74, 761-764.	6.2	288
9	Overall Genomic Pattern Is a Predictor of Outcome in Neuroblastoma. Journal of Clinical Oncology, 2009, 27, 1026-1033.	1.6	288
10	Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. Journal of Clinical Oncology, 2017, 35, 2580-2587.	1.6	219
11	Increased Risk of Systemic Relapses Associated With Bone Marrow Micrometastasis and Circulating Tumor Cells in Localized Ewing Tumor. Journal of Clinical Oncology, 2003, 21, 85-91.	1.6	203
12	Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Annals of Oncology, 2010, 21, 1834-1838.	1.2	188
13	Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncology, The, 2009, 10, 663-671.	10.7	176
14	Emergence of New ALK Mutations at Relapse of Neuroblastoma. Journal of Clinical Oncology, 2014, 32, 2727-2734.	1.6	176
15	Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. British Journal of Cancer, 2012, 107, 1418-1422.	6.4	151
16	Two distinct deleted regions on the short arm of chromosome I in neuroblastoma. Genes Chromosomes and Cancer, 1994, 10, 275-281.	2.8	144
17	Accumulation of Segmental Alterations Determines Progression in Neuroblastoma. Journal of Clinical Oncology, 2010, 28, 3122-3130.	1.6	142
18	An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours. Oncogene, 2010, 29, 3583-3592.	5.9	141

#	Article	IF	Citations
19	Prognostic Impact of Gene Expressionâ€“Based Classification for Neuroblastoma. Journal of Clinical Oncology, 2010, 28, 3506-3515.	1.6	129
20	Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma. Clinical Cancer Research, 2018, 24, 939-949.	7.0	127
21	Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma. Clinical Cancer Research, 2016, 22, 5564-5573.	7.0	108
22	Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours. Nature Reviews Cancer, 2019, 19, 420-438.	28.4	98
23	Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden. Nature Communications, 2021, 12, 3230.	12.8	95
24	Transcription Factor E3 and Transcription Factor EB Renal Cell Carcinomas: Clinical Features, Biological Behavior and Prognostic Factors. Journal of Urology, 2011, 185, 24-29.	0.4	91
25	Recent insights into the biology of neuroblastoma. International Journal of Cancer, 2014, 135, 2249-2261.	5.1	91
26	TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets. Nature Communications, 2018, 9, 4866.	12.8	91
27	Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma. Oncotarget, 2014, 5, 2688-2702.	1.8	89
28	Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature. Clinical Cancer Research, 2010, 16, 1532-1541.	7.0	86
29	Molecular pathogenesis of peripheral neuroblastic tumors. Oncogene, 2010, 29, 1566-1579.	5.9	84
30	Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative) Tj ETQq0 0 0 rgBT Overlock 10 Tf 50	6.4	82
31	Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers. Clinical Cancer Research, 2015, 21, 1904-1915.	7.0	80
32	Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. Journal of the National Cancer Institute, 2018, 110, 1084-1093.	6.3	73
33	Opsoclonusâ€“myoclonus in children associated or not with neuroblastoma. European Journal of Paediatric Neurology, 2010, 14, 400-409.	1.6	72
34	Detection of tumor <scp>ALK</scp> status in neuroblastoma patients using peripheral blood. Cancer Medicine, 2015, 4, 540-550.	2.8	65
35	Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis. Clinical Cancer Research, 2015, 21, 4913-4921.	7.0	62
36	Imageâ€defined risk factor assessment of neurogenic tumors after neoadjuvant chemotherapy is useful for predicting intraâ€operative risk factors and the completeness of resection. Pediatric Blood and Cancer, 2015, 62, 1543-1549.	1.5	61

#	Article	IF	Citations
37	Gene expression profiling of 1p35â€“36 genes in neuroblastoma. Oncogene, 2004, 23, 5912-5922.	5.9	60
38	Implementation of mechanism of action biology-driven early drug development for children with cancer. European Journal of Cancer, 2016, 62, 124-131.	2.8	58
39	Mosaicism for oncogenic G12D KRAS mutation associated with epidermal nevus, polycystic kidneys and rhabdomyosarcoma. Journal of Medical Genetics, 2010, 47, 859-862.	3.2	57
40	Malformations, genetic abnormalities, and wilms tumor. Pediatric Blood and Cancer, 2014, 61, 140-144.	1.5	57
41	Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma:ÂA study from the International Neuroblastoma Risk Group database. European Journal of Cancer, 2016, 65, 1-10.	2.8	56
42	Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors. Pediatric Blood and Cancer, 2017, 64, e26365.	1.5	56
43	The pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children: a review. European Journal of Pediatrics, 2020, 179, 191-202.	2.7	55
44	Characterization of Rearrangements Involving the ALK Gene Reveals a Novel Truncated Form Associated with Tumor Aggressiveness in Neuroblastoma. Cancer Research, 2013, 73, 195-204.	0.9	54
45	Combined 24-color karyotyping and comparative genomic hybridization analysis indicates predominant rearrangements of early replicating chromosome regions in neuroblastoma. Cancer Genetics and Cytogenetics, 2003, 141, 32-42.	1.0	53
46	Risk stratification of highâ€risk metastatic neuroblastoma: A report from the HRâ€NBLâ€1/SIOPEN study. Pediatric Blood and Cancer, 2018, 65, e27363.	1.5	53
47	Update on Pediatric Opsoclonus Myoclonus Syndrome. Neuropediatrics, 2013, 44, 324-329.	0.6	51
48	Hypertension in Childhood Cancer. Journal of Pediatric Hematology/Oncology, 2006, 28, 659-664.	0.6	50
49	WNT/Î²â€catenin pathway activation in Wilms tumors: A unifying mechanism with multiple entries?. Genes Chromosomes and Cancer, 2009, 48, 816-827.	2.8	50
50	Minimally invasive surgery of neuroblastic tumors in children: Indications depend on anatomical location and imageâ€defined risk factors. Pediatric Blood and Cancer, 2015, 62, 257-261.	1.5	50
51	Treatment and outcome of patients with relapsed clear cell sarcoma of the kidney: a combined SIOP and AIEOP study. British Journal of Cancer, 2014, 111, 227-233.	6.4	49
52	Riskâ€adapted therapy for infantile myofibromatosis in children. Pediatric Blood and Cancer, 2012, 59, 115-120.	1.5	47
53	Desmoplastic small round cell tumors with EWSâ€WT1 fusion transcript in children and young adults. Pediatric Blood and Cancer, 2012, 58, 891-897.	1.5	45
54	From class waivers to precision medicine in paediatric oncology. Lancet Oncology, The, 2017, 18, e394-e404.	10.7	45

#	Article	IF	Citations
55	Management of Wilms tumors in Drash and Frasier syndromes. Pediatric Blood and Cancer, 2009, 52, 55-59.	1.5	43
56	Exosomal microRNAs from Longitudinal Liquid Biopsies for the Prediction of Response to Induction Chemotherapy in High-Risk Neuroblastoma Patients: A Proof of Concept SIOPEN Study. Cancers, 2019, 11, 1476.	3.7	43
57	The challenge of defining â€œultraâ€highâ€riskâ€•neuroblastoma. Pediatric Blood and Cancer, 2019, 66, e27556.	1.5	43
58	Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. European Journal of Cancer, 2020, 136, 52-68.	2.8	42
59	Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study. Journal of Clinical Oncology, 2021, 39, 2552-2563.	1.6	42
60	Breakpoint Features of Genomic Rearrangements in Neuroblastoma with Unbalanced Translocations and Chromothripsis. PLoS ONE, 2013, 8, e72182.	2.5	42
61	Role of chemotherapy resistance genes in outcome of neuroblastoma. Pediatric Blood and Cancer, 2007, 48, 311-317.	1.5	41
62	Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project. Journal of Clinical Oncology, 2020, 38, 1906-1918.	1.6	41
63	Radiogenomics of neuroblastomas: Relationships between imaging phenotypes, tumor genomic profile and survival. PLoS ONE, 2017, 12, e0185190.	2.5	40
64	CGH analysis of secondary genetic changes in Ewing tumors:. Cancer Genetics and Cytogenetics, 2001, 130, 57-61.	1.0	39
65	Characterization of amplicons in neuroblastoma: Highâ€resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes. Genes Chromosomes and Cancer, 2008, 47, 819-834.	2.8	39
66	A Multilocus Technique for Risk Evaluation of Patients with Neuroblastoma. Clinical Cancer Research, 2011, 17, 792-804.	7.0	39
67	Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification. British Journal of Cancer, 2015, 112, 290-295.	6.4	39
68	ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome. European Journal of Human Genetics, 2012, 20, 291-297.	2.8	38
69	Relevance of a molecular tumour board (MTB) for patientsâ€™ enrolment in clinical trials: experience of the Institut Curie. ESMO Open, 2018, 3, e000339.	4.5	37
70	Circulating tumor DNA analysis enables molecular characterization of pediatric renal tumors at diagnosis. International Journal of Cancer, 2019, 144, 68-79.	5.1	37
71	Stepwise occurrence of a complex unbalanced translocation in neuroblastoma leading to insertion of a telomere sequence and late chromosome 17q gain. Oncogene, 2005, 24, 3377-3384.	5.9	36
72	Variety and complexity of chromosome 17 translocations in neuroblastoma. Genes Chromosomes and Cancer, 2004, 39, 143-150.	2.8	35

#	Article	IF	Citations
73	Preoperative Wilms tumor rupture. Cancer, 2008, 113, 202-213.	4.1	35
74	Clinical relevance of loss of heterozygosity of the short arm of chromosome 1 in neuroblastoma: A single-institution study. , 1996, 69, 73-78.		34
75	Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies. European Journal of Cancer, 2021, 157, 198-213.	2.8	34
76	Preferential Occurrence of Chromosome Breakpoints within Early Replicating Regions in Neuroblastoma. Cell Cycle, 2005, 4, 1842-1846.	2.6	33
77	Learning smoothing models of copy number profiles using breakpoint annotations. BMC Bioinformatics, 2013, 14, 164.	2.6	33
78	Long-term side effects of radiotherapy for pediatric localized neuroblastoma. Strahlentherapie Und Onkologie, 2015, 191, 604-612.	2.0	32
79	Indications and results of diagnostic biopsy in pediatric renal tumors: A retrospective analysis of 317 patients with critical review of SIOP guidelines. Pediatric Blood and Cancer, 2019, 66, e27641.	1.5	31
80	Clinical characteristics and outcomes of children with WAGR syndrome and Wilms tumor and/or nephroblastomatosis: The 30â€year SIOPâ€RTSG experience. Cancer, 2021, 127, 628-638.	4.1	30
81	Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). Journal of Clinical Oncology, 2021, 39, 3377-3390.	1.6	30
82	Determination of 17q gain in patients with neuroblastoma by analysis of circulating DNA. Pediatric Blood and Cancer, 2011, 56, 757-761.	1.5	29
83	Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. Expert Opinion on Drug Discovery, 2017, 12, 1-11.	5.0	28
84	Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients. JCI Insight, 2018, 3, .	5.0	28
85	Meta-mining of copy number profiles of high-risk neuroblastoma tumors. Scientific Data, 2018, 5, 180240.	5.3	27
86	Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma. Oncotarget, 2016, 7, 1960-1972.	1.8	26
87	Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	26
88	Diagnostic and prognostic information obtained on fineâ€needle aspirates of primary neuroblastic tumors. Cancer Cytopathology, 2011, 119, 411-423.	2.4	23
89	Minimally invasive classification of paediatric solid tumours using reduced representation bisulphite sequencing of cell-free DNA: a proof-of-principle study. Epigenetics, 2021, 16, 196-208.	2.7	23
90	IL10RA Modulates Crizotinib Sensitivity in NPM1-ALK-positive Anaplastic Large Cell Lymphoma. Blood, 2020, 136, 1657-1669.	1.4	22

#	Article	IF	Citations
91	QuantumClone: clonal assessment of functional mutations in cancer based on a genotype-aware method for clonal reconstruction. Bioinformatics, 2018, 34, 1808-1816.	4.1	20
92	Identification of differentALKmutations in a pair of neuroblastoma cell lines established at diagnosis and relapse. Oncotarget, 2016, 7, 87301-87311.	1.8	20
93	Is Nephron Sparing Surgery Justified in Wilms Tumor With Beckwithâ€“Wiedemann Syndrome or Isolated Hemihypertrophy?. Pediatric Blood and Cancer, 2016, 63, 1571-1577.	1.5	19
94	First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSÃ©-ESMART trial. European Journal of Cancer, 2021, 157, 268-277.	2.8	19
95	Clinical Characteristics and Outcome of Patients with Neuroblastoma Presenting Genomic Amplification of Loci Other than MYCN. PLoS ONE, 2014, 9, e101990.	2.5	17
96	Study of chromatin remodeling genes implicates SMARCA4 as a putative player in oncogenesis in neuroblastoma. International Journal of Cancer, 2019, 145, 2781-2791.	5.1	16
97	The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples. European Journal of Cancer, 2022, 160, 12-23.	2.8	16
98	High Cyclin E Staining Index in Blastemal, Stromal or Epithelial Cells Is Correlated with Tumor Aggressiveness in Patients with Nephroblastoma. PLoS ONE, 2008, 3, e2216.	2.5	15
99	Oncologic Phenotype of Peripheral Neuroblastic Tumors Associated With PHOX2B Nonâ€Polyalanine Repeat Expansion Mutations. Pediatric Blood and Cancer, 2016, 63, 71-77.	1.5	14
100	From Wilms to kidney tumors: which ones require a biopsy?. Pediatric Radiology, 2020, 50, 1049-1051.	2.0	14
101	Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalinâ€Fixed Paraffinâ€Embedded Tissue Samples and Are Associated With Recurrence. Pediatric Blood and Cancer, 2016, 63, 1019-1023.	1.5	13
102	Infant cancers in France: Incidence and survival (2000â€“2014). Cancer Epidemiology, 2020, 65, 101697.	1.9	13
103	Parental smoking, maternal alcohol consumption during pregnancy and the risk of neuroblastoma in children. A pooled analysis of the ESCALE and ESTELLE French studies. International Journal of Cancer, 2019, 145, 2907-2916.	5.1	12
104	Infantile Rhabdomyosarcomas With VGLL2 Rearrangement Are Not Always an Indolent Disease. American Journal of Surgical Pathology, 2021, 45, 854-867.	3.7	12
105	Highly Sensitive Detection Method of Retinoblastoma Genetic Predisposition and Biomarkers. Journal of Molecular Diagnostics, 2021, 23, 1714-1721.	2.8	12
106	Feasibility of Busulfan Melphalan and Stem Cell Rescue After 131I-MIBG and Topotecan Therapy for Refractory or Relapsed Metastatic Neuroblastoma: The French Experience. Journal of Pediatric Hematology/Oncology, 2018, 40, 426-432.	0.6	11
107	Genomic Profiles of Neuroblastoma Associated With Opsoclonus Myoclonus Syndrome. Journal of Pediatric Hematology/Oncology, 2018, 40, 93-98.	0.6	11
108	Data Resource Profile: The French Childhood Cancer Observation Platform (CCOP). International Journal of Epidemiology, 2020, 49, 1434-1435k.	1.9	11

#	Article	IF	Citations
109	SegAnnDB: interactive Web-based genomic segmentation. Bioinformatics, 2014, 30, 1539-1546.	4.1	10
110	Intraâ€•and extraâ€cranial <scp>BCORâ€ITD</scp> tumours are separate entities within the <scp>BCOR</scp>â€rearranged family. Journal of Pathology: Clinical Research, 2022, 8, 217-232.	3.0	10
111	Autologous haematopoietic stem cell transplantation for paediatric solid tumours. Best Practice and Research in Clinical Haematology, 1999, 12, 247-259.	1.7	9
112	Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group. Journal of Clinical Oncology, 2020, 38, 3685-3697.	1.6	9
113	Crizotinib in children and adolescents with advanced ROS1, MET, or ALK-rearranged cancer: Results of the AcSÃ© phase II trial.. Journal of Clinical Oncology, 2016, 34, 11509-11509.	1.6	9
114	Metastatic neuroblastoma in a patient with ROHHAD: A new alert regarding the risk of aggressive malignancies in this rare condition. Pediatric Blood and Cancer, 2019, 66, e27906.	1.5	8
115	Environmental exposures related to parental habits in the perinatal period and the risk of Wilms' tumor in children. Cancer Epidemiology, 2020, 66, 101706.	1.9	8
116	Abstract CT004: European pediatric precision medicine program in recurrent tumors: first results from MAPPYACTS molecular profiling trial towards AcSe-ESMART proof-of-concept study. , 2017, , .		8
117	Molecular diagnosis of retinoblastoma by circulating tumor DNA analysis. European Journal of Cancer, 2021, 154, 277-287.	2.8	7
118	Analysis of genomic alterations in neuroblastoma by multiplex ligation-dependent probe amplification and array comparative genomic hybridization: a comparison of results. Cancer Genetics, 2012, 205, 657-664.	0.4	6
119	Longâ€term results of the transmanubrial osteomuscularâ€sparing approach for pediatric tumors. Pediatric Blood and Cancer, 2017, 64, e26527.	1.5	6
120	Enrollment in earlyâ€phase clinical trials in pediatric oncology: The experience at Institut Curie. Pediatric Blood and Cancer, 2018, 65, e26916.	1.5	6
121	A Dilated Cardiomyopathy Revealing a Neuroblastoma: Which Link?. Journal of Pediatric Hematology/Oncology, 2016, 38, e251-e253.	0.6	5
122	ALK mutation dynamics and clonal evolution in a neuroblastoma model exhibiting two ALK mutations. Oncotarget, 2019, 10, 4937-4950.	1.8	5
123	Efficacy of Lorlatinib in Primary Crizotinib-Resistant Adult Neuroblastoma Harboring ALK Y1278S Mutation. JCO Precision Oncology, 2019, 3, 1-5.	3.0	5
124	Maternal and perinatal characteristics, congenital malformations and the risk of wilms tumor: the ESTELLE study. Cancer Causes and Control, 2020, 31, 491-501.	1.8	4
125	A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma. Cancers, 2021, 13, 1807.	3.7	4
126	Two cases of localized neuroblastoma with multiple segmental chromosomal alterations and metastatic progression. Pediatric Blood and Cancer, 2013, 60, 332-335.	1.5	3

#	Article	IF	Citations
127	Bone Vertebrae Metastases With Spinal Cord Compression. Journal of Pediatric Hematology/Oncology, 2015, 37, e387-e389.	0.6	3
128	Pediatric Patient With Renal Cell Carcinoma Treated by Successive Antiangiogenics Drugs: A Case Report and Review of the Literature. Journal of Pediatric Hematology/Oncology, 2017, 39, e279-e284.	0.6	3
129	Abstract CT081: Pediatric precision medicine program in recurrent tumors: Results of the first 500 patients included in the European MAPPYACTS molecular profiling trial. Cancer Research, 2019, 79, CT081-CT081.	0.9	3
130	Can pediatric and adolescent patients with recurrent tumors benefit from a precision medicine program? The European MAPPYACTS experience.. Journal of Clinical Oncology, 2019, 37, 10018-10018.	1.6	3
131	Reply to comment on: The diagnostic accuracy and clinical utility of pediatric renal tumor biopsy: Report of the UK experience in the SIOP UK WT2001 trial. Pediatric Blood and Cancer, 2019, 66, e27828.	1.5	2
132	NTRK Alterations in Pediatric High-Risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug Targets. JCO Precision Oncology, 2021, 5, 450-454.	3.0	2
133	Kids Enter the MATCH. Journal of the National Cancer Institute, 2017, 109, djw305.	6.3	1
134	Abstract 4952: Whole exome sequencing of circulating tumor DNA highlights spatial and temporal tumor heterogeneity in neuroblastoma. , 2017, , .		1
135	A neuroblastoma risk classification model for developing countries: A study from the International Neuroblastoma (NB) Risk Group (INRG) database.. Journal of Clinical Oncology, 2014, 32, 10030-10030.	1.6	1
136	Treatment and outcome of patients with relapsed clear cell sarcoma of the kidney (CCSK): A combined SIOP and AIEOP study.. Journal of Clinical Oncology, 2014, 32, 10041-10041.	1.6	1
137	Information sur le stockage et lâ€™utilisation des Ã©chantillons biologiques en oncologie pÃ©diatrique. Revue D'Oncologie HÃ©matologie PÃ©diatrique, 2015, 3, 123-124.	0.1	0
138	Neuroblastoma: Diagnosis and Treatment. , 2018, , 1-1.		0
139	Reply to K. Beiske et al. Journal of Clinical Oncology, 2020, 38, 3720-3721.	1.6	0
140	Emergence of new ALK mutations at relapse of neuroblastoma.. Journal of Clinical Oncology, 2014, 32, 11006-11006.	1.6	0
141	Abstract 2980: Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. , 2015, , .		0
142	Risk prediction based on post induction bone marrow response and genomic profile: A new way to stratify stage M neuroblastoma patients?. Journal of Clinical Oncology, 2018, 36, 10550-10550.	1.6	0
143	Abstract 2592: Whole-exome sequencing cell free DNA analysis documents new tumor specific alterations at relapse of high-risk pediatric cancers. , 2018, , .		0
144	Biology of Neuroblastoma. , 2020, , 17-28.		0

#	Article	IF	Citations
145	Prognostic impact of postoperative 123I-metaiodobenzylguanidine scintigraphy: added value of SPECT/CT and semiquantification of the uptake at the surgical site. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 131-138.	0.7	0
146	INSP-15. ITCC-P4: A sustainable platform of molecularly well-characterized PDX models of pediatric cancers for high throughputin vivo testing. Neuro-Oncology, 2022, 24, i189-i189.	1.2	0